Duration of response, PFS, and time to progression in the IRd and placebo-Rd groups according to cytogenetic subgroup
| Patients (N, ixazomib vs placebo group) . | Median duration of response, mo . | Median PFS, mo . | Median time to progression, mo . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| IRd . | Placebo-Rd . | IRd . | Placebo-Rd . | HR . | 95% CI . | IRd . | Placebo-Rd . | HR . | |
| All (360 vs 362) | 20.5 (n = 282) | 15.0 (n = 259) | 20.6 | 14.7 | 0.742 | 0.587-0.939 | 21.4 | 15.7 | 0.712 |
| Standard risk (199 vs 216) | NR (n = 160) | 15.0 (n = 158) | 20.6 | 15.6 | 0.640 | 0.462-0.888 | 20.6 | 15.9 | 0.626 |
| High risk* (75 vs 62) | 20.5 (n = 59) | 11.3 (n = 37) | 21.4 | 9.7 | 0.543 | 0.321-0.918 | 21.4 | 12.0 | 0.534 |
| del(17p)† (36 vs 33) | 20.5 (n = 26) | 12.0 (n = 16) | 21.4 | 9.7 | 0.596 | 0.286-1.243 | 21.4 | 12.9 | 0.590 |
| t(4;14) alone (36 vs 25) | 17.5 (n = 32) | 7.2 (n = 19) | 18.5 | 12.0 | 0.645 | 0.250-1.663 | 18.5 | 12.0 | 0.645 |
| Amp 1q21 alone (80 vs 92) | 16.6 (n = 56) | 11.3 (n = 63) | 15.4 | 11.3 | 0.781 | 0.492-1.240 | 16.4 | 12.3 | 0.787 |
| Expanded high risk‡ (155 vs 154) | 20.5 (n = 115) | 11.3 (n = 100) | 17.5 | 11.1 | 0.664 | 0.474-0.928 | 18.5 | 12.1 | 0.672 |
| Patients (N, ixazomib vs placebo group) . | Median duration of response, mo . | Median PFS, mo . | Median time to progression, mo . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| IRd . | Placebo-Rd . | IRd . | Placebo-Rd . | HR . | 95% CI . | IRd . | Placebo-Rd . | HR . | |
| All (360 vs 362) | 20.5 (n = 282) | 15.0 (n = 259) | 20.6 | 14.7 | 0.742 | 0.587-0.939 | 21.4 | 15.7 | 0.712 |
| Standard risk (199 vs 216) | NR (n = 160) | 15.0 (n = 158) | 20.6 | 15.6 | 0.640 | 0.462-0.888 | 20.6 | 15.9 | 0.626 |
| High risk* (75 vs 62) | 20.5 (n = 59) | 11.3 (n = 37) | 21.4 | 9.7 | 0.543 | 0.321-0.918 | 21.4 | 12.0 | 0.534 |
| del(17p)† (36 vs 33) | 20.5 (n = 26) | 12.0 (n = 16) | 21.4 | 9.7 | 0.596 | 0.286-1.243 | 21.4 | 12.9 | 0.590 |
| t(4;14) alone (36 vs 25) | 17.5 (n = 32) | 7.2 (n = 19) | 18.5 | 12.0 | 0.645 | 0.250-1.663 | 18.5 | 12.0 | 0.645 |
| Amp 1q21 alone (80 vs 92) | 16.6 (n = 56) | 11.3 (n = 63) | 15.4 | 11.3 | 0.781 | 0.492-1.240 | 16.4 | 12.3 | 0.787 |
| Expanded high risk‡ (155 vs 154) | 20.5 (n = 115) | 11.3 (n = 100) | 17.5 | 11.1 | 0.664 | 0.474-0.928 | 18.5 | 12.1 | 0.672 |